S&P Futures
4,280.25 -6.25 (-0.15%) Dow Futures
33,951.00 -30.00 (-0.09%) Nasdaq Futures
13,499.75 -23.50 (-0.17%) Russell 2000 Futures
1,996.40 -5.30 (-0.26%) Crude Oil
90.64 +0.14 (+0.15%) Gold
1,768.90 -2.30 (-0.13%)
NanoString Technologies, Inc. (NSTG)
After hours:
Chart Events
Performance Outlook
| Previous Close | 14.63 |
| Open | 14.65 |
| Bid | 14.00 x 1000 |
| Ask | 16.66 x 1800 |
| Day's Range | 13.98 - 14.68 |
| 52 Week Range | 11.12 - 62.34 |
| Volume | |
| Avg. Volume | 815,069 |
| Market Cap | 670.91M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.78 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NSTG
Related Research
- NanoString Technologies, Inc.Analyst Report: Bio-Rad Laboratories, Inc.Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.RatingFair ValueEconomic Moatlast yearMorningstar
- Business Wire
Study Using NanoString’s GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics
SEATTLE, August 09, 2022--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a peer-reviewed paper published in Nature Genetics using the GeoMx Human Whole Transcriptome Atlas (WTA) to construct a high-resolution molecular landscape of pancreatic cancer. This paper, along with a tissue image generated using the GeoMx® Digital Spatial Profiler (DSP), is featured on the cover of the August 2022 edition of
- Simply Wall St.
Does NanoString Technologies (NASDAQ:NSTG) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Zacks
Wall Street Analysts Think NanoString (NSTG) Could Surge 116%: Read This Before Placing a Bet
The consensus price target hints at an 116.4% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
